Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs.

[1]  R. Nusse,et al.  Wnt signaling: a common theme in animal development. , 1997, Genes & development.

[2]  Amie Y Lee,et al.  Wnt2 as a new therapeutic target in malignant pleural mesothelioma , 2005, International journal of cancer.

[3]  I. Ng,et al.  Upregulation of the Wnt Co-Receptor LRP6 Promotes Hepatocarcinogenesis and Enhances Cell Invasion , 2012, PloS one.

[4]  Yonghe Li,et al.  Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells. , 2012, Cellular signalling.

[5]  K. Imanaka,et al.  Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis , 2009, Journal of Gastroenterology.

[6]  Yusuke Nakamura,et al.  AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1 , 2000, Nature Genetics.

[7]  J. Rubin,et al.  Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas , 2002, Oncogene.

[8]  D. Stolz,et al.  Hepatocyte γ-catenin compensates for conditionally deleted β-catenin at adherens junctions. , 2011, Journal of hepatology.

[9]  R. Nusse,et al.  The nucleotide sequence of the human int‐1 mammary oncogene; evolutionary conservation of coding and non‐coding sequences. , 1985, The EMBO journal.

[10]  A. Üren,et al.  Secreted Frizzled-related Protein-1 Binds Directly to Wingless and Is a Biphasic Modulator of Wnt Signaling* , 2000, The Journal of Biological Chemistry.

[11]  R. Kemler,et al.  The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. , 1989, The EMBO journal.

[12]  S. Imbeaud,et al.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.

[13]  D. Kimelman,et al.  β-Catenin destruction complex: insights and questions from a structural perspective , 2006, Oncogene.

[14]  Alison Rowe,et al.  Wise, a context-dependent activator and inhibitor of Wnt signalling , 2003, Development.

[15]  J. Herman,et al.  WNT10B functional dualism: beta-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer. , 2007, Molecular biology of the cell.

[16]  H. Koga,et al.  Noncanonical Wnt11 Inhibits Hepatocellular Carcinoma Cell Proliferation and Migration , 2010, Molecular Cancer Research.

[17]  G. Dontu,et al.  Mammary stem cells, self-renewal pathways, and carcinogenesis , 2005, Breast Cancer Research.

[18]  J. Luk,et al.  Dickkopf 4 (DKK4) acts on Wnt/β-catenin pathway by influencing β-catenin in hepatocellular carcinoma , 2012, Oncogene.

[19]  H. Dinh,et al.  A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. , 2012, Cancer research.

[20]  B. Daniele,et al.  Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .

[21]  Z. Trajanoski,et al.  Evolution of genomic instability in diethylnitrosamine‐induced hepatocarcinogenesis in mice , 2011, Hepatology.

[22]  F. Takahashi‐Yanaga,et al.  Drug Development Targeting the Glycogen Synthase Kinase-3β (GSK-3β)-Mediated Signal Transduction Pathway: Inhibitors of the Wnt/β-Catenin Signaling Pathway as Novel Anticancer Drugs , 2009 .

[23]  R. Benarous,et al.  The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. , 1999, Current biology : CB.

[24]  M. Ozturk,et al.  Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells , 2009, Molecular Cancer.

[25]  W. Weis,et al.  β-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation , 2005, Nature Structural &Molecular Biology.

[26]  L. Patthy,et al.  The WIF module. , 2000, Trends in biochemical sciences.

[27]  Amie Y Lee,et al.  Efficacy of Wnt-1 monoclonal antibody in sarcoma cells , 2005, BMC Cancer.

[28]  M. Fukuzawa,et al.  In vitro RNA interference against beta-catenin inhibits the proliferation of pediatric hepatic tumors. , 2006, International journal of oncology.

[29]  R. S. Goldstein,et al.  Resistance or sensitivity of Wilms’ tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target , 2011, Oncogene.

[30]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[31]  Derek Y. Chiang,et al.  Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. , 2009, Cancer research.

[32]  H Clevers,et al.  All Tcf HMG box transcription factors interact with Groucho-related co-repressors. , 2001, Nucleic acids research.

[33]  Nazim Madhavji,et al.  Organization , 2020, WER.

[34]  B. Cieply,et al.  siRNA-Mediated β-Catenin Knockdown in Human Hepatoma Cells Results in Decreased Growth and Survival* , 2007 .

[35]  M. Kojiro,et al.  β ‐Catenin expression in hepatocellular carcinoma: A possible participation of β ‐catenin in the dedifferentiation process , 2002 .

[36]  J. Nathans,et al.  Vascular Development in the Retina and Inner Ear Control by Norrin and Frizzled-4, a High-Affinity Ligand-Receptor Pair , 2004, Cell.

[37]  Sangdun Choi,et al.  Mouse Cristin/R-spondin Family Proteins Are Novel Ligands for the Frizzled 8 and LRP6 Receptors and Activate β-Catenin-dependent Gene Expression* , 2006, Journal of Biological Chemistry.

[38]  T. A. Graham,et al.  Crystal structure of a beta-catenin/Tcf complex. , 2000, Cell.

[39]  Lawrence Lum,et al.  Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer , 2008, Nature chemical biology.

[40]  R. Benarous,et al.  The F-box protein β-TrCP associates with phosphorylated β-catenin and regulates its activity in the cell , 1999, Current Biology.

[41]  S. Hirohashi,et al.  Identification of a neural α-catenin as a key regulator of cadherin function and multicellular organization , 1992, Cell.

[42]  K. Uematsu,et al.  An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. , 2007, Cancer research.

[43]  J. Llovet,et al.  Medical therapies for hepatocellular carcinoma: a critical view of the evidence , 2013, Nature Reviews Gastroenterology &Hepatology.

[44]  J. Wands,et al.  Overexpression of insulin receptor substrate‐1 and hepatitis Bx genes causes premalignant alterations in the liver , 2009, Hepatology.

[45]  Xi He,et al.  Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. , 2002, Cell.

[46]  Hang Zhang,et al.  Proliferation and migration mediated by Dkk-1/Wnt/beta-catenin cascade in a model of hepatocellular carcinoma cells. , 2007, Translational research : the journal of laboratory and clinical medicine.

[47]  A. Zorn,et al.  Different thresholds of Wnt-Frizzled 7 signaling coordinate proliferation, morphogenesis and fate of endoderm progenitor cells. , 2013, Developmental biology.

[48]  Li-hua Hu,et al.  Knockdown of BMI-1 causes cell-cycle arrest and derepresses p16INK4a, HOXA9 and HOXC13 mRNA expression in HeLa cells , 2011, Medical oncology.

[49]  S. Weintraub,et al.  Wnt Antagonist SFRP1 Functions as a Secreted Mediator of Senescence , 2012, Molecular and Cellular Biology.

[50]  A. Cadoret,et al.  Hepatomegaly in Transgenic Mice Expressing an Oncogenic Form of β-Catenin , 2001 .

[51]  Xi He,et al.  SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor* , 2005, Journal of Biological Chemistry.

[52]  Naoto Ueno,et al.  The TAK1-NLK Mitogen-Activated Protein Kinase Cascade Functions in the Wnt-5a/Ca2+ Pathway To Antagonize Wnt/β-Catenin Signaling , 2003, Molecular and Cellular Biology.

[53]  Xi He,et al.  Control of β-Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism , 2002, Cell.

[54]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[55]  Nobuyuki Onishi,et al.  The receptor tyrosine kinase Ror2 is involved in non‐canonical Wnt5a/JNK signalling pathway , 2003, Genes to cells : devoted to molecular & cellular mechanisms.

[56]  R. Hannoush,et al.  Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. , 2013, Cancer research.

[57]  X. Wang,et al.  Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma , 2013, Hepatology.

[58]  M. Kahn,et al.  γ-Catenin at adherens junctions: mechanism and biologic implications in hepatocellular cancer after β-catenin knockdown. , 2013, Neoplasia.

[59]  A. Cadoret,et al.  Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. , 2001, Cancer research.

[60]  R. Gebhardt,et al.  Organ patterning in the adult stage: The role of Wnt/β‐catenin signaling in liver zonation and beyond , 2009, Developmental dynamics : an official publication of the American Association of Anatomists.

[61]  W. Birchmeier,et al.  Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. , 2010, Cold Spring Harbor perspectives in biology.

[62]  Harold E. Varmus,et al.  Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome , 1982, Cell.

[63]  W. Park,et al.  Mutations of β‐catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[64]  M. Taketo,et al.  Hepatocarcinogenesis in Mice with β-Catenin and Ha-Ras Gene Mutations , 2004, Cancer Research.

[65]  Q. Xiong,et al.  Promoter methylation and mRNA expression of DKK-3 and WIF-1 in hepatocellular carcinoma. , 2009, World journal of gastroenterology.

[66]  V. Chopra,et al.  Effect of the Wingless (wg1) mutation on wing and haltere development in Drosophila melanogaster. , 1976, Developmental biology.

[67]  J. Chen,et al.  beta-catenin siRNA regulation of apoptosis- and angiogenesis-related gene expression in hepatocellular carcinoma cells: potential uses for gene therapy. , 2010, Oncology reports.

[68]  C. Schmitt.  Senescence, apoptosis and therapy — cutting the lifelines of cancer , 2003, Nature Reviews Cancer.

[69]  S. Thorgeirsson,et al.  Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors. , 2011, Cancer research.

[70]  M. Buendia,et al.  Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[71]  S. C. Schuyler,et al.  Sonic hedgehog antagonists induce cell death in acute myeloid leukemia cells with the presence of lipopolysaccharides, tumor necrosis factor-α, or interferons , 2013, Investigational New Drugs.

[72]  Christof Niehrs,et al.  Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. , 2002, Nature.

[73]  K. Uematsu,et al.  Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells , 2004, Oncogene.

[74]  V. Mazzaferro,et al.  Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib , 2012, Clinical Cancer Research.

[75]  J. Campisi,et al.  Cancer and aging: a model for the cancer promoting effects of the aging stroma. , 2002, The international journal of biochemistry & cell biology.

[76]  B. Cieply,et al.  SiRNA‐Mediated β‐catenin Knockdown in Human Hepatoma Cells Results in Their Decreased Growth and Survival , 2007, Neoplasia.

[77]  T. A. Graham,et al.  Crystal Structure of a β-Catenin/Tcf Complex , 2000, Cell.

[78]  Wei Dong Chen,et al.  Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer , 2004, Nature Genetics.

[79]  David I. Smith,et al.  Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas , 2002, Oncogene.

[80]  Susan Grepper,et al.  Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin , 2011, Molecular Cancer.

[81]  M. Matsuda,et al.  β-Catenin Mutations Are Frequent in Human Hepatocellular Carcinomas Associated with Hepatitis C Virus Infection , 1999 .

[82]  Marc W. Kirschner,et al.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.

[83]  C. Dai,et al.  Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine‐45 mutant β‐catenin , 2010, Hepatology.

[84]  Xi He,et al.  Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.

[85]  Y. Chung,et al.  Small Molecule-Based Promotion of PKCα-Mediated β-Catenin Degradation Suppresses the Proliferation of CRT-Positive Cancer Cells , 2012, PloS one.

[86]  M. Taketo,et al.  Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. , 2002, Cancer research.

[87]  Jie J. Zheng,et al.  Characterization of the Kremen-binding Site on Dkk1 and Elucidation of the Role of Kremen in Dkk-mediated Wnt Antagonism* , 2008, Journal of Biological Chemistry.

[88]  Sucha Singh,et al.  Conditional β‐catenin loss in mice promotes chemical hepatocarcinogenesis: Role of oxidative stress and platelet‐derived growth factor receptor α/phosphoinositide 3‐kinase signaling , 2010, Hepatology.

[89]  Riccardo Lencioni,et al.  Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.

[90]  M. Waterman,et al.  Diversity of LEF/TCF action in development and disease , 2006, Oncogene.

[91]  T. Pramila,et al.  Interaction of Frizzled Related Protein (FRP) with Wnt Ligands and the Frizzled Receptor Suggests Alternative Mechanisms for FRP Inhibition of Wnt Signaling* , 1999, The Journal of Biological Chemistry.

[92]  A. Buchmann,et al.  Tumor formation in liver of conditional β-catenin-deficient mice exposed to a diethylnitrosamine/phenobarbital tumor promotion regimen. , 2011, Carcinogenesis.

[93]  Bruce A. Yankner,et al.  β-Trcp couples β-catenin phosphorylation-degradation and regulates Xenopus axis formation , 1999 .

[94]  Christof Niehrs,et al.  Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling , 2002, Nature.

[95]  M. Taketo,et al.  Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. , 2004, Cancer research.

[96]  Amie Y Lee,et al.  A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. , 2004, Neoplasia.

[97]  K. Sugimachi,et al.  A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[98]  R. Kuruvilla,et al.  Frizzled3 Is Required for Neurogenesis and Target Innervation during Sympathetic Nervous System Development , 2011, The Journal of Neuroscience.

[99]  Bruce J. Melancon,et al.  Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. , 2010, Nature chemical biology.

[100]  M. Matsuda,et al.  Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. , 1999, The American journal of pathology.

[101]  E. Yu,et al.  Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. , 2008, Journal of hepatology.

[102]  Samuel So,et al.  Small molecule antagonists of Tcf4/β‐catenin complex inhibit the growth of HCC cells in vitro and in vivo , 2010, International journal of cancer.

[103]  C. Tzeng,et al.  Wnt-1 Protein as a Prognostic Biomarker for Hepatitis B–Related and Hepatitis C–Related Hepatocellular Carcinoma after Surgery , 2009, Cancer Epidemiology Biomarkers & Prevention.

[104]  Juanjuan Shan,et al.  Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. , 2009, Cancer research.

[105]  A. Bell,et al.  Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. , 2005, Gastroenterology.

[106]  Ping Chen,et al.  Planar cell polarity signaling in vertebrates , 2007, BioEssays : news and reviews in molecular, cellular and developmental biology.

[107]  S. Fan,et al.  β‐catenin mutation and overexpression in hepatocellular carcinoma , 2001 .

[108]  E. Wagner,et al.  Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. , 2008, The Journal of clinical investigation.

[109]  Hong Ma,et al.  A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[110]  Sejal M. Patel,et al.  R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6 , 2007, Proceedings of the National Academy of Sciences.

[111]  H. Varmus,et al.  A new nomenclature for int-1 and related genes: The Wnt gene family , 1991, Cell.

[112]  M. Aoki,et al.  Hepatocellular carcinoma development induced by conditional β‐catenin activation in Lkb1+/− mice , 2009, Cancer science.

[113]  Gregory A. Wyant,et al.  Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy , 2012, Proceedings of the National Academy of Sciences.

[114]  H. Clevers.  Wnt/beta-catenin signaling in development and disease. , 2006, Cell.

[115]  P. Adler,et al.  A Drosophila tissue polarity locus encodes a protein containing seven potential transmembrane domains , 1989, Nature.

[116]  P. Hainaut,et al.  Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma , 2008, British Journal of Cancer.

[117]  M. Yu,et al.  Epidemiology of hepatocellular carcinoma. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[118]  S. Fan,et al.  beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. , 2001, Cancer.

[119]  R. Nusse,et al.  Purified Wnt5a Protein Activates or Inhibits β-Catenin–TCF Signaling Depending on Receptor Context , 2006, PLoS biology.

[120]  S. Imbeaud,et al.  Next-generation sequencing identified new oncogenes and tumor suppressor genes in human hepatic tumors , 2012, Oncoimmunology.

[121]  G. Thomas,et al.  Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. , 2001, Gastroenterology.

[122]  M. Fischer,et al.  Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors , 2012, Proceedings of the National Academy of Sciences.

[123]  G. Piazza,et al.  Niclosamide Suppresses Cancer Cell Growth By Inducing Wnt Co-Receptor LRP6 Degradation and Inhibiting the Wnt/β-Catenin Pathway , 2011, PloS one.

[124]  Satdarshan P. S. Monga,et al.  Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of β-catenin. , 2011, Journal of hepatology.

[125]  Yan Li,et al.  Role of PKCβ in hepatocellular carcinoma cells migration and invasion in vitro: a potential therapeutic target , 2008, Clinical & Experimental Metastasis.

[126]  Ying Chen,et al.  Therapeutic Potential of a Monoclonal Antibody Blocking the Wnt Pathway in Diabetic Retinopathy , 2012, Diabetes.

[127]  K. Uematsu,et al.  An Anti-Wnt-2 Monoclonal Antibody Induces Apoptosis in Malignant Melanoma Cells and Inhibits Tumor Growth , 2004, Cancer Research.

[128]  Susan Grepper,et al.  Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells , 2009, Molecular Cancer.

[129]  Robert A. Weinberg,et al.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. , 2008, Developmental cell.

[130]  Joerg Huelsken,et al.  The Wnt signalling pathway , 2002, Journal of Cell Science.

[131]  C. Jomary,et al.  Secreted Frizzled-related proteins: searching for relationships and patterns. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[132]  M. Chevallier,et al.  Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. , 2011, Journal of hepatology.

[133]  Amie Y Lee,et al.  Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations , 2005, Oncogene.

[134]  Wei Zhang,et al.  Frizzled7 as an emerging target for cancer therapy. , 2012, Cellular signalling.

[135]  Miran Kim,et al.  Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. , 2004, Gastroenterology.

[136]  鈴木 哲也.  Beta-catenin expression in hepatocellular carcinoma : A possible participation of beta-catenin in the dedifferentiation process , 2002 .

[137]  H. Ohdan,et al.  An Anti-Wnt5a Antibody Suppresses Metastasis of Gastric Cancer Cells In Vivo by Inhibiting Receptor-Mediated Endocytosis , 2011, Molecular Cancer Therapeutics.

[138]  H. Yao,et al.  Targeting the Wnt/β-catenin signaling pathway in human cancers , 2011, Expert opinion on therapeutic targets.

[139]  R. Moon,et al.  WNT signalling pathways as therapeutic targets in cancer , 2012, Nature Reviews Cancer.

[140]  C. Lobe,et al.  Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. , 2005, Cancer research.

[141]  J. Simon,et al.  A small-molecule inhibitor of Tcf/β-catenin signaling down-regulates PPARγ and PPARδ activities , 2008, Molecular Cancer Therapeutics.

[142]  S. Angers,et al.  Inhibition of Tankyrases Induces Axin Stabilization and Blocks Wnt Signalling in Breast Cancer Cells , 2012, PloS one.

[143]  F. Takahashi‐Yanaga,et al.  Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: inhibitors of the Wnt/beta-catenin signaling pathway as novel anticancer drugs. , 2009, Journal of pharmacological sciences.

[144]  Yun Deng,et al.  Epigenetic silencing of WIF-1 in hepatocellular carcinomas , 2010, Journal of Cancer Research and Clinical Oncology.